July
2008 Newsletter
#88 (v. 9, 7)
PCNG
Prostate Cancer Networking Group of Greater Cincinnati
PCNG (pcngcincinnati.org)
is a chapter of USTOO (www.ustoo.com)
Founder: Bob Kanter - Convener: Tom Young – Newsletter:
450 copies this issue - Editor: Kees DeJong
Facilitators: Stan Moczydlowski: 8/’03; Steven Plymire: 9/’03; Jerry Glenn:
1/’04; Jack Ramsay: 5/’04;
Dick Fencl: 5/’05;: Jerry Bryan: 2/’07; Librarian:
Stan Moczydlowski; Reviewers: Frits Roos, Daniel White
Telephone contacts:
|
751-6888 Kees DeJong: 1996 (56), PSA 24, GS 9; IAD; EBRT+Brachy, IAD, AD, ketoconazole+HC, Leukine, estradiol patches; Taxotere, carboplatin, Avastin, Emcyt |
|
528-2769 Gordon Huntley:1999, PSA 4, GS 9; RP & Orchiectomy |
|
272-1820 Dick Fencl: 2003, PSA 14, GS 6, EBRT+Brachy |
|
733-5745 Bill Riggs: 1995, |
|
221-6736 John Hoffmann: 1997, PSA 5, GS 6; RP, EBRT |
|
984-3343 Tom Young: 2002, PSA 7.8, GS 6; RP |
19/20xx: year of diagnosis; PSA: Prostate Specific Antigen;
GS: Gleason Score; RP: Radical Prostatectomy;
EBRT: External Beam Radiation Therapy; Brachy: Brachytherapy ('seeds'),
and AD: Hormonal Therapy: Androgen Deprivation
Carol Cappiello
is a partner of a PC patient; she will be happy to answer any questions about
PC,
in particular from other partners
Our 20th APC Meeting will be
held before the Large Meeting
Men with Advanced Prostate Cancer, please, come!!
From 5.30 to 6.30 pm; bring your spouses/partners, some food will be served.
The next Large Group Meeting Will Be Held on Wednesday, July 30th
Women Are Very Much Welcome!!
6.30--7.00 p.m.: hospitality and networking
7.00--7.30 p.m.: new members and sharing
7.30 p.m.:
PART 2:
Great Cost of Cancer Treatment Requires
Knowledge of Medicaid: The New Medicaid Rules.
Also: Trusts for Beneficiaries.
Mark S. Reckman, Esq.Mark Reckman has been with Wood & Lamping since 1977 as a law clerk and since 1979 as an attorney. He has served in every management role at Wood & Lamping, including Managing Partner. Mr. Reckman sits on the Good Samaritan Hospital Foundation Board and is also Chairman of the Board of Columbia Savings Bank. In 2006 Mark was named as a Super Lawyer for the State of Ohio by Law and Politics magazine.
8.30--9.00 p.m.: hospitality and networking
Next Small Discussion Group Meeting (for Men only) will be
held on
Wednesday, August 13th, from 7.00-9.00 pm at the Wellness Community
Mark Reckman will present part 2 of his talk
Mark Reckman did such a great job last month; he’s coming
back by popular demand. Please get in touch with him with questions he
can address this month.
His contact information is as follows:
Msreckman@woodlamping.com;
Phone: (513)852-6054; Fax: (513) 852-6087.
In August, our speaker is Alan V. Safdi, M.D,. of Greater
Cincinnati Gastroenterology Associates, Inc. Alan is a prostate cancer
survivor and will discuss his work-out routine and nutritional habits since
being treated. More on this to come….
Tom Young
Hormonal Treatment versus Watchful Waiting
Are you in the late seventies and diagnosed with prostate cancer? Your best option might be to do nothing, also known as conservative management or watchful waiting. That is the conclusion in an article in the July 2008 issue of the Journal of the American Medical Association:
CONTEXT:
Despite a lack of data, increasing numbers of patients are receiving primary
androgen deprivation therapy (PADT) as an alternative to surgery, radiation,
or conservative management for the treatment of localized prostate cancer.
OBJECTIVE: To evaluate the association between PADT and survival in elderly
men with localized prostate cancer.
DESIGN, SETTING, AND PATIENTS:
A population-based cohort study of 19,271 men aged 66 years or older
receiving Medicare who did not receive definitive local therapy for clinical
stage T1-T2 prostate cancer. These patients were diagnosed in 1992-2002
within predefined US geographical areas, with follow-up through December 31,
2006, for all-cause mortality and through December 31, 2004, for prostate
cancer-specific mortality. ...
RESULTS:
Among patients with localized prostate cancer (median age, 77 years), 7867
(41%) received PADT, and 11,404 were treated with conservative management,
not including PADT. During the follow-up period, there were 1560 prostate
cancer deaths and 11,045 deaths from all causes. Primary androgen
deprivation therapy was associated with lower 10-year prostate
cancer-specific survival (80.1% vs 82.6% ...) and no increase in 10-year
overall survival (30.2% vs 30.3% ...) compared with conservative management.
However, in a prespecified subset analysis, PADT use in men with poorly
differentiated cancer was associated with improved prostate cancer-specific
survival (59.8% vs 54.3% ...) but not overall survival (17.3% vs 15.3% ...).
CONCLUSION:
Primary androgen deprivation therapy is not associated with improved
survival among the majority of elderly men with localized prostate cancer
when compared with conservative management.
Does a Diagnosis of Prostate Cancer Change Enrollment in the Managed Care Programs of Medicare?
Satisfaction in either Medicare or Managed Care appears
similar, though in the 2 years after diagnosis, prostate cancer patients
were slightly less likely to disenroll from Medicare Managed Care than
their matched cancer-free peers.
Later this year Medicare patients will have a chance to disenroll from
Medicare into a Managed Care program. The following, from a July 2008
article, in the J. Nat. Cancer Inst., is a must reading for those
contemplating a change in care.
Elkin EB et al.: J Natl Cancer Inst. 2008 Jul 8, 1013-21.
“Disenrollment From Medicare Managed Care
Among Beneficiaries With and Without a Cancer Diagnosis.”
“Managed care was
introduced to the Medicare program with the hope that competition between
plans would help to control escalating costs, expand preventive services,
and improve coordination of care. During the 1990s, the number of Medicare
beneficiaries participating in managed care increased substantially, from
1.3 million (4% of beneficiaries) in 1990 to 6.3 million (16% of
beneficiaries) in 2000. Although the availability of plans and beneficiary
participation vary geographically, more than 80% of Medicare beneficiaries
now have access to at least one managed care plan.
Managed care organizations generally aim to improve disease prevention
and management while containing the costs of care. However, the mechanisms
that they use to achieve these goals, such as primary care gatekeeping,
provider networks, and higher cost sharing for out-of-network services, may
restrict enrollees’ access to specific providers and create barriers or
disincentives to the use of expensive services. These mechanisms may deter
enrollment and retention of individuals with chronic or complex diseases,
particularly conditions for which access to specialized treatment centers or
physicians is perceived as advantageous. Numerous studies have found that
Medicare managed care plans tend to attract and retain beneficiaries who are
younger and healthier and have lower pre-enrollment medical expenditures
than beneficiaries in the traditional Medicare indemnity insurance (ie,
"fee-for-service") program . Survey results indicate that voluntary
disenrollment from a Medicare managed care plan may reflect beneficiaries’
perceptions of poor quality of care, impaired access to services or
providers, or overall dissatisfaction with their plans.
With more than 55% of all cancer diagnoses and 70% of all cancer deaths
occurring in people aged 65 years or older, the experience of cancer
patients in the Medicare program is of particular concern. Cancer patients
and survivors typically require regular visits with specialists,
coordination of care among multiple providers, and frequent testing to
monitor disease. For the past decade, there has been increasing emphasis on
the value of provider expertise in treating complex medical conditions such
as cancer. Because managed care plans may constrain enrollees’ choice of
providers, participation in Medicare managed care may feel especially
restrictive to enrollees with cancer. Problems with access have been
correlated with beneficiary dissatisfaction and may also prompt
disenrollment.
The percent of beneficiaries with prostate cancer (solid line) and
without prostate cancer (dashed line) who remained continuously enrolled in
Medicare managed care after a cancer diagnosis..
The Am. Cancer Society, http://cancer.org, estimates that in 2008, in the USA, 186,320 new cases of prostate cancer will be diagnosed; 28,660 men will die of this disease = 15 % of the new cases. Compare this percentage with that for lung cancer: in 2007 213,380 new cases and 160,390 deaths = 75 % of the new cases, or pancreatic cancer: 37,170 new cases and 33,370 deaths = 90 % of the new cases
click
on the underlined references in the HTML or PDF editions of this
newsletter for additional information
google
‘PCNG’
and find our Home Page, Newsletter Archive, and the page linking to 100+ Prostate Cancer Web Sites
PCNG: PROSTATE CANCER NETWORKING GROUP
of Greater Cincinnati
c/o The Wellness Community
4918 Cooper Road
Cincinnati, OH 45242